Kidney Transplant in India and UAE | Complete Patient Guide

ELIGIBILITY CRITERIA (RECIPIENT):

• Confirmed end-stage renal disease (eGFR < 15 mL/min/1.73 m²) or rapidly progressive CKD approaching ESRD

• Patients currently on hemodialysis or peritoneal dialysis, or pre-emptive transplant candidates

• ABO blood group compatibility confirmed (ABO-incompatible protocols available at select centers with plasmapheresis and rituximab desensitization)

• Negative complement-dependent cytotoxicity (CDC) crossmatch and flow cytometry crossmatch

• Panel reactive antibody (PRA) levels assessed; highly sensitized patients (PRA > 80%) require virtual crossmatch and may need desensitization

• Age: typically 2–70 years; carefully selected older recipients evaluated case-by-case

• Adequate cardiac reserve (left ventricular ejection fraction ≥ 40%, or optimized prior to listing)

• No active malignancy (minimum 2–5 year cancer-free interval depending on tumor type, per Kidney Disease: Improving Global Outcomes [KDIGO] guidelines)

• No active systemic infection or untreated tuberculosis

• BMI ideally < 35 kg/m² (centers vary; weight loss support offered for higher BMI candidates)

• Psychosocial clearance and demonstrated medication adherence capacity

REQUIRED PRE-TRANSPLANT DIAGNOSTIC WORKUP:

• Complete metabolic panel, CBC, coagulation profile, HbA1c

• Renal ultrasound with Doppler; DTPA/DMSA nuclear scan for residual function assessment

• 2D Echocardiography (ECHO): assess LV function, valvular disease, pulmonary hypertension

• Dobutamine stress ECHO or myocardial perfusion imaging (MPI/SPECT) for patients with diabetes or cardiovascular risk

• Coronary angiography if stress test positive or high-risk profile

• CT angiography of iliac vessels (assess atherosclerotic burden and vessel caliber for anastomosis planning)

• Tissue typing: HLA-A, B, C, DR, DQ by next-generation sequencing (NGS)

• PRA / calculated PRA (cPRA) and DSA panel

• Serologies: HIV, HBsAg, Anti-HCV, HCV RNA, CMV IgG/IgM, EBV, HSV, VZV, HTLV-1/2, RPR/VDRL

• Urological evaluation: voiding cystourethrogram (VCUG) or urodynamic study if lower urinary tract dysfunction suspected

• Cancer screening per age/sex: PSA, mammogram, Pap smear, colonoscopy, chest CT (endemic mycoses or TB exposure)

• Dental clearance and ophthalmology review

CONTRAINDICATIONS (ABSOLUTE):

• Active malignancy without adequate disease-free interval

• Untreated or active systemic infection (sepsis, active TB, uncontrolled HIV)

• Severe irreversible cardiac or pulmonary dysfunction precluding surgery

• Active substance use disorder without documented rehabilitation

• Non-compliance history with life-threatening implications and no viable support system

• Recent myocardial infarction (within 3–6 months, unrevascularized)

LIVING DONOR EVALUATION (ADDITIONAL):

• 24-hour urine protein, eGFR ≥ 80 mL/min/1.73 m²

• CT angiogram of donor kidneys (vascular anatomy, stone disease, anomalies)

• Psychological assessment and independent donor advocacy team (IDAT) clearance

• Blood pressure, metabolic syndrome screening, age typically 18–60 years

STANDARD OPEN KIDNEY TRANSPLANTATION (HETEROTOPIC):

The conventional approach involves a curvilinear Gibson incision in the right or left iliac fossa (right preferred for easier vascular access). The external iliac artery and vein are dissected extraperitoneally. End-to-side arterial and venous anastomoses are created using fine polypropylene sutures (5-0 or 6-0 Prolene). The ureter is tunneled submucosally into the bladder dome (Lich-Grégoir technique) with a double-J ureteral stent placed to protect the anastomosis, typically removed at 4–6 weeks post-operatively via cystoscopy. Cold ischemia time (CIT) is minimized by coordinated procurement and bench preparation; machine perfusion (hypothermic or normothermic) is increasingly used for marginal or extended-criteria donor (ECD) kidneys to assess viability and reduce DGF risk.

MINIMALLY INVASIVE & ROBOTIC APPROACHES:

• Robotic-Assisted Kidney Transplantation (RAKT): Pioneered at select high-volume centers (including institutions in India such as Medanta and Manipal Hospitals, and in the UAE at Cleveland Clinic Abu Dhabi), RAKT uses the da Vinci Surgical System to perform the entire transplant procedure intracorporeally through small ports. Benefits include significantly reduced wound complications, lower rates of lymphocele and incisional hernia, minimized blood loss, and faster functional recovery—particularly advantageous for obese recipients (BMI > 30) and those with prior pelvic surgery. Warm ischemia time with robotic technique is comparable to open surgery in experienced hands (< 40 minutes).

• Hand-Assisted Laparoscopic Donor Nephrectomy (HALDN) and Pure Laparoscopic Donor Nephrectomy (PLDN): Standard of care for living donors; reduces donor convalescence to 2–3 weeks versus 4–6 weeks for open donor nephrectomy, with equivalent long-term donor outcomes.

• Robotic Donor Nephrectomy: Available at select centers; further reduces donor morbidity and improves cosmesis.

IMMUNOSUPPRESSION PROTOCOLS:

• Induction Therapy: Basiliximab (IL-2 receptor antagonist, standard risk) or rabbit ATG/thymoglobulin (high immunologic risk: high PRA, repeat transplant, DCD/ECD kidneys); some centers use belatacept induction.

• Maintenance: Tacrolimus extended-release (Envarsus XR or Advagraf) preferred over twice-daily formulations for improved adherence; mycophenolate mofetil (MMF) 1–1.5 g twice daily or enteric-coated mycophenolate sodium (EC-MPS); prednisolone with planned taper. Steroid-avoidance or steroid-withdrawal protocols used in low-risk recipients at specialized centers.

• Adjunct Agents: mTOR inhibitors (everolimus, sirolimus) used in calcineurin inhibitor minimization strategies, particularly for recipients with CNI nephrotoxicity or post-transplant malignancy risk.

• Desensitization Protocols (Highly Sensitized / ABO-Incompatible): Rituximab + plasmapheresis (therapeutic plasma exchange) ± intravenous immunoglobulin (IVIG); some centers use bortezomib or eculizumab for antibody-mediated rejection rescue.

ANTI-REJECTION TREATMENT:

• Acute Cellular Rejection (ACR): IV methylprednisolone pulse (500 mg × 3 days); ATG for steroid-resistant ACR.

• Antibody-Mediated Rejection (AMR): Plasmapheresis + IVIG ± rituximab; emerging agents include ravulizumab (C5 complement inhibitor) and imlifidase (IgG-cleaving enzyme) in investigational protocols at leading centers.

SPECIALIZED PROGRAMS:

• Paired Kidney Exchange (PKE) / Kidney Paired Donation (KPD): Available through national registries in India (NOTTO) and UAE (Hayat program), enabling incompatible donor-recipient pairs to swap donors.

• Simultaneous Kidney-Pancreas Transplant (SPK): For Type 1 diabetic ESRD patients; available at select centers in India and the UAE.

• Pediatric Kidney Transplantation: Requires specialized surgical adaptation (adult donor kidney into pediatric recipient via midline transperitoneal approach with aorta/IVC anastomosis); available at dedicated pediatric nephrology-transplant programs.

PHASE 1 — REMOTE WORKUP & CASE REVIEW (WEEKS 1–4, BEFORE TRAVEL):

• GAF Healthcare coordinates submission of all medical records, current dialysis adequacy reports (Kt/V), and imaging to the assigned transplant nephrologist and surgeon.

• Virtual consultation conducted; preliminary HLA typing and crossmatch logistics discussed.

• If a living donor is traveling with the patient, donor workup documentation is reviewed simultaneously.

• Travel clearance, e-Medical visa application (India) or medical visa facilitation (UAE) initiated.

• Financial estimate, surgery date tentatively scheduled.

PHASE 2 — ARRIVAL & PRE-TRANSPLANT EVALUATION (DAYS 1–7 IN-COUNTRY):

• Day 1: Airport transfer arranged by GAF Healthcare; admission or hotel accommodation for initial workup.

• Days 1–3: Comprehensive recipient evaluation including repeat crossmatch (CDC and flow cytometry), DSA panel, updated ECHO, cardiac stress test if indicated, anesthesia review, dental clearance.

• Days 3–5: Donor admission; laparoscopic donor nephrectomy workup (CT angiogram, split renal function scan, urology and nephrology clearance, IDAT interview).

• Days 5–7: Final multidisciplinary transplant committee review (nephrologist, transplant surgeon, anesthesiologist, transplant coordinator, social worker). Informed consent process; immunosuppression pre-loading initiated (tacrolimus started 48–72 hours pre-operatively to achieve therapeutic levels).

PHASE 3 — SURGICAL DAY (DAY 8, APPROXIMATELY):

• Donor laparoscopic (or robotic) nephrectomy performed under general anesthesia; kidney retrieved and flushed with cold University of Wisconsin (UW) or Custodiol HTK preservation solution.

• Back-table preparation (bench surgery): renal artery/vein dissected, excess perinephric fat removed, vessels prepared for anastomosis.

• Recipient heterotopic transplant surgery (open or robotic, 3–4 hours): iliac vessel anastomoses, ureteroneocystostomy, double-J stent placement.

• Reperfusion: kidney turns pink and begins producing urine on the table (living donor); excellent early graft function indicator.

• ICU admission for 12–24 hours post-operatively for hemodynamic monitoring.

PHASE 4 — EARLY POST-OPERATIVE PERIOD (DAYS 9–21, INPATIENT):

• Day 1 post-op: Foley catheter in situ; strict fluid balance monitoring; hourly urine output targets (> 100 mL/hr initially).

• Days 1–3: Central venous pressure (CVP)-guided fluid management; tacrolimus trough levels daily; creatinine trending.

• Days 3–7: Progressive ambulation; Foley removed day 3–5 if urine output stable; oral immunosuppression consolidated.

• Surveillance: daily renal function tests, tacrolimus levels, CBC, electrolytes; Doppler ultrasound of graft at 24–48 hours, 1 week, and before discharge.

• Rejection surveillance: Any unexplained rise in creatinine > 25% above nadir triggers clinical assessment; biopsy (Tru-cut 18G automated needle under ultrasound guidance) performed if rejection suspected.

• Prophylaxis: Valganciclovir (CMV prophylaxis 3–6 months), TMP-SMX (PCP prophylaxis 6–12 months), fluconazole or nystatin (fungal prophylaxis 1–3 months), low-dose aspirin (thromboprophylaxis), LMWH until fully ambulatory.

• Donor recovery: Laparoscopic donor discharged day 5–7; light activity resumed at 2–3 weeks.

• Discharge criteria: stable creatinine trending downward, tacrolimus in therapeutic range, no fever, independent oral intake, wound healing satisfactory.

PHASE 5 — OUTPATIENT MONITORING IN-COUNTRY (WEEKS 3–8):

• Twice-weekly clinic visits: renal function panel, tacrolimus trough, CBC, urine culture, wound check.

• Week 4–6: Double-J ureteral stent removal via flexible cystoscopy (outpatient, 15 minutes, local anesthesia).

• CMV PCR monitoring fortnightly if high-risk (D+/R-).

• Immunosuppression dose titration; prednisolone taper per protocol.

• Target creatinine established (typically 0.8–1.6 mg/dL for ideal graft; varies by donor age and size).

• Education: patients and caregivers trained on tacrolimus timing, drug interactions (avoid CYP3A4 inhibitors/inducers), infection signs, and sun protection (skin cancer risk).

PHASE 6 — FIT-TO-FLY ASSESSMENT (WEEK 6–8):

• Creatinine stable for minimum 2 consecutive weeks at or near nadir.

• No active infection, no rejection episode requiring IV therapy in preceding 4 weeks.

• Immunosuppression doses stable and therapeutic.

• Discharge summary, complete medication list, tacrolimus level log, and emergency contact protocol provided.

• GAF Healthcare arranges return flight in economy class (aisle seat preferred); compression stockings and adequate hydration advised; DVT prophylaxis protocol provided.

• Remote follow-up plan established with patient's home nephrologist via telemedicine handover coordinated by GAF Healthcare.

LONG-TERM MILESTONES:

• 3 months: Protocol biopsy (many centers); DSA panel; CMV prophylaxis ends.

• 6 months: Return to light work; driving (check local regulations); nephrology follow-up frequency reduced.

• 12 months: Annual review; cancer screening; bone density scan; lipid and cardiovascular risk optimization.

• 5 years: 80–85% graft survival (living donor); continued annual surveillance for chronic allograft nephropathy, post-transplant diabetes mellitus (PTDM), and cardiovascular events.